Valneva IPO Presentation Deck

VLA15: Exclusive, Worldwide Partnering Deal with Pfizer Collaboration with Pfizer for Late Stage Development and Future Commercialization Pfizer funding 70% of development costs through program completion Valneva eligible to receive a total of $308 million upfront and milestone payments ($140 million received to date) Valneva to receive tiered royalties starting at 19% Valneva - Roadshow Presentation V 2Pfizer April 2021 15

View entire presentation